CARTs targeting fibroblast activation protein-α (FAP), a tumor stromal-associated antigen expressed by CAFs, delivered in combination with an EphA2-targeting CAR population was shown to control the tumor growth in an A549 lung cancer model more effectively than either agent alone (37). This evidence concerns the gene EPHA2 and neoplasm.